A new study has found that about half of patients diagnosed with metastatic lung cancer are not receiving treatment, despite significant advances in available therapies for the disease.

Lung cancer remains the leading cause of cancer deaths in the United States. While new drugs and treatment options have improved outcomes for many patients with advanced stages of the disease, the research suggests these therapies are not reaching a substantial portion of those who could potentially benefit.

The findings highlight a gap between the availability of newer cancer treatments and their actual implementation in patient care. Metastatic lung cancer, which refers to cancer that has spread beyond the lungs to other parts of the body, has historically carried a poor prognosis.

The study's results raise questions about access to care, treatment decision-making processes, and potential barriers that may prevent patients from receiving available therapies. Factors that could contribute to treatment gaps may include patient health status, age, geographic location, insurance coverage, and healthcare system capacity.

Researchers did not immediately specify the methodology of the study or provide detailed breakdown of patient demographics and reasons for non-treatment. The findings underscore ongoing challenges in cancer care delivery despite therapeutic advances in recent years.